Please use this identifier to cite or link to this item:
Title: The NACSTOP trial: A multi-center, cluster-controlled trial of early cessation of acetylcysteine in acetaminophen overdose.
Austin Authors: Wong, Anselm ;McNulty, Richard;Taylor, David McD ;Sivilotti, Marco L A;Greene, Shaun L ;Gunja, Naren;Koutsogiannis, Zeff ;Graudins, Andis 
Affiliation: School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia
Department of Medicine, University of Melbourne, Victoria, Australia
Austin Toxicology Service, Austin Health, Heidelberg, Victoria, Australia
Department of Emergency Medicine, Blacktown and Mount Druitt hospitals, Western Sydney Toxicology Service, NSW, Australia
Department of Emergency Medicine, Austin Health, Heidelberg, Victoria, Australia
Departments of Emergency and of Biomedical & Molecular Sciences, Queen's University, Kingston, Ontario, Canada
Victorian Poisons Information Centre, Austin Health, Heidelberg, Victoria, Australia
Western Sydney Toxicology Service, Sydney Medical School, NSW, Australia
Monash Toxicology Service and Monash Emergency Research Collaborative, Dandenong Hospital, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia
Issue Date: 2019 2018-08-19
Publication information: Hepatology (Baltimore, Md.) 2019; 69(2): 774-784
Abstract: Historically, acetylcysteine has been delivered at a fixed dose and duration of 300 mg/kg over 20 hours to nearly every patient deemed to be at any risk for hepatotoxicity following acetaminophen overdose. We investigated a 12-hour treatment regimen for selected low-risk patients. This was a multicenter, open-label, cluster-controlled trial at six metropolitan emergency departments. We enrolled subjects following single or staggered acetaminophen overdose with normal serum alanine transaminase (ALT) and creatinine on presentation and at 12 hours, and acetaminophen <20mg/L at 12 hours. Patients were allocated to intervention (250 mg/kg over 12-hour) or control (300 mg/kg over 20-hour) regimens by site. incidence of "hepatic injury" 20 hours post-initiation of acetylcysteine treatment; defined as ALT doubling and peak ALT > 100 IU/L, indicating the need for further antidotal treatment. Secondary outcomes included incidence of hepatotoxicity (ALT > 1000 IU/L), peak INR and adverse drug reactions. Of 449 acetaminophen overdoses receiving acetylcysteine, 100 were recruited to the study. Time to acetylcysteine (median 7 hours [IQR 6,12] vs 7 hours [6,10]) and initial acetaminophen (124 mg/L [58,171] vs 146 mg/L [66,204]) were similar between intervention and control groups. There was no difference in ALT (18 IU/L [13,22] vs 16 IU/L [13,21]) or INR (1.2 vs 1.2) 20 hours after starting acetylcysteine between groups. No patients developed hepatic injury or hepatotoxicity in either group (OR 1·0 [95% CI 0.02,50]). No patients re-presented with liver injury, none died and 96/96 were well at 14-day telephone follow-up. Discontinuing acetylcysteine based on laboratory testing after 12 hours of treatment is feasible and likely safe in selected patients at very low risk of liver injury from acetaminophen overdose. This article is protected by copyright. All rights reserved.
DOI: 10.1002/hep.30224
ORCID: 0000-0002-7423-2467
PubMed URL: 30125376
Type: Journal Article
Subjects: N-acetylcysteine
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.